SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Frédéric Chopin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFrédéric Chopin
Date of birth1810-03-01
IdentifiersMRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845
Document date1838-07-21
AuthorMatthias Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End-of-treatment review after 119 doses. [S]

History of Present Illness

Mr. Chopin returns five days after his 119th and last dose. He took every dose on his video calls, 56 in the intensive phase and 63 in the continuation phase, finishing in 17 weeks. The two-month culture grew nothing, so he has two consecutive negative cultures. The cold he had in June cleared within ten days. He has no cough, sputum, fever, night sweats, or blood, and he weighs 55.0 kg, 6.5 kg more than at diagnosis. He had no tendon pain or tingling at any point. Between the sick visit and today there was no clinic review; the health department nurse asked about symptoms and side effects on every video call. He is teaching his full schedule of fifteen students and has started practicing for a small recital. [S]

ElementDetail
Treatment119 of 119 doses observed, completed in 17 weeks
CulturesThird-week and two-month cultures negative
Weight55.0 kg, up 6.5 kg since diagnosis
WorkTeaching fifteen students a week

Review of Systems

SystemResultFinding
RespiratoryNegativeNo cough, sputum, hemoptysis, or breathlessness
ConstitutionalNegativeNo fever, night sweats, or weight loss
MusculoskeletalNegativeNo tendon pain
NeurologicalNegativeNo numbness or tingling
PsychiatricNegativeMood good; PHQ-9 3; no thoughts of suicide or self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses)Oral route1838-03-20 to 1838-07-16completedS
Moxifloxacin 400 mg tablet, one tablet daily400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours afterOral route1838-03-20 to 1838-07-16completedS
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeksOral route1838-03-20 to 1838-07-16completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg)Oral route1838-03-20 to 1838-05-14completedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1838-03-20 to 1838-07-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1838-07-21Body height170cmS
1838-07-21Body weight55kgS
1838-07-21Body mass index (BMI) [Ratio]19kg/m2S
1838-07-21Systolic blood pressure110mm[Hg]S
1838-07-21Diastolic blood pressure70mm[Hg]S
1838-07-21Heart rate72/minS
1838-07-21Respiratory rate14/minS
1838-07-21Body temperature36.6CelS
1838-07-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1838-07-21Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
1838-07-21Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
1838-07-21Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-56 U/LNormalS
1838-07-21Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 1838-07-21; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 55.0 kg, BMI 19.0
RespiratoryClear, with no crackles
AbdomenLiver not enlarged
MusculoskeletalTendons non-tender
NeurologicalNormal sensation and fine finger movements

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and cultureresolvedconfirmed R04.2S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit.
Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic.
Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dLresolvedconfirmed E44.0S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion.
Acute viral upper respiratory infection during the continuation phase of tuberculosis treatment; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness chosen to teach how to tell a cold from tuberculosis treatment failure, and moxifloxacin interactions with cold remedies; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsEvery visitCompleted todayNo symptoms
ExaminationWeight, with the pyrazinamide dose checked against the weight bandMonthlyCompleted today55.0 kg
Medication safetyAdverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluidsEvery visitCompleted todayNone at any visit or video call
ExaminationClinical review (adherence, symptoms, adverse effects, weight)At least monthly during treatmentDeferredNo clinic review between the sick visit in early June and today, about six weeks, because the schedule went from the end of the intensive phase to the end of treatment. The nurse reviewed symptoms and side effects on every video call, and today's examination, weight, and tests are normal, so no harm is evident. Corrective action: monthly clinic reviews booked at the start of treatment for every patient on the four-month regimen
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin)Completed todayALT 22 U/L at the end of treatment
LaboratoryHemoglobin and albuminAt the end of treatment when low at baselineCompleted todayHemoglobin 14.1 g/dL; albumin 4.0 g/dL
LaboratorySputum acid-fast smear and cultureBaseline, then monthly until two consecutive cultures are negativeCompleted todayTwo consecutive negative cultures (third week and two months); no further sputum needed
LaboratoryTwo-month sputum cultureAt the end of the intensive phase; a positive result needs evaluation and repeat susceptibility testingCompleted todayNo growth
ImagingChest X-rayBaseline; at two months only if baseline cultures were negative; end of treatment optionalCompleted todayCavity closed; small area of right upper lobe scarring
Medication safetyDoses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months)Every visitCompleted today119 doses in 17 weeks, within five months
ReferralNotification of treatment completionAt the end of treatmentCompleted todaySent to the health department today
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentCompleted today3, item 9 scored 0
Self-managementNutrition: dietitian, intake, supplement drinksEvery visit until weight is restoredCompleted todayWeight goal met; supplements stopped
ReferralInfectious diseases reviewAt diagnosis, at two months, and at the end of treatmentCompleted todayResults reviewed by message; no routine follow-up

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Adult preventive visit in about two months. Same-day visit for symptoms of relapse. Next scheduled visit 1838-09-15: adult preventive visit. [S]